Table 2.

Additional Clinical Trials of Nicotinic Agents in ADHD.

Study [reference #]	Sample Sizea	Female	Age Mean (SD)	Research Design	Smoking Status	Duration of Treatment	Nicotinic Treatment	1° Clinical Endpoint	1° Clinical Measure Met (Y/N), Effect Size	Reason for Exclusion from Table 1
Gehricke [42]	52	29%	27 (7.9)	RPCT Within	Both	2 day	Nicotine	e-diary self-reportb	Yes, N/A	No clinician rating of ADHD
Gehricke [53]	10	50%	25 (6.2)	RPCT Within	Abstinent Smokers	2 day	Nicotine	e-diary self-reportb	Yes, N/A	No clinician rating of ADHD, abstinent smokers
Wilens [58]	13	31%	26 (18.6)c	Open label	unspecified	12 week	Adjunct Donepezil	CGI	No, N/A	Open label; Not a nicotinic agonist
Wilens [57]	5	0%	8 - 17	Case Series	Non-Smokers	8-26 weeks	Adjunct Donepezil	CGI	Yes, N/A	Retrospective case series (open label); not a nicotinic agonist
Biederman [56]	36	50%	35.9 (7.8)	RPCT Between	N/A	12 week	Galantamine	CGI	No, N/A	Not a nicotinic agonist

^aSample Size refers to number analyzed in the primary clinical measure (% Female and Age are from reported demographics)

^bThere was no specified primary endpoint – effects on ADHD symptoms were reported as positive (see original article)

^cThis study included both children and adults, however as the results did not differ by age they are reported together

Abbreviations: RPCT = Randomized Placebo Controlled Trial; Between = between subjects; Within = within subjects; N/A = not available; CPRS = Conner's Parent Rating Scale; CGI = Clinical Global Impression; AISRS = ADHD Investigator Symptom Report Scale; CAARS-INV = Conner's Adult ADHD Rating Scale, Investigator; ADHD-RS-IV (HV) TS = ADHD Rating Scale-IV Home Version; ARS = ADHD Rating Scale